Organizational Structure

CRIETO accomplishments

Number of supported seeds (accumulated): 294 seeds

Examples

Next-generation Fetal ECG monitoring system

IRIS MONITOR®

Joint R&D partner: Atom Medical Cooperation

This is a successfully commercialized next-generation fetal ECG monitoring system based on the work of Professor Yoshitaka Kimura, Advanced Interdisciplinary Biomedical Engineering, Tohoku University School of Medicine. IRIS MONITOR, a heart rate monitor capable of non-invasively measuring fetal heart rate through the mother’s abdominal wall, is the world’s first such system to be successfully applied within clinical trials from the 24th week of pregnancy. Developed entirely in Japan within a perinatal clinical environment, IRIS MONITOR comes as a result of industry-academic collaboration in all facets of development, IP management, clinical trials, and commercialization. The development, commercialization and overseas expansion of genuine domestically made medical equipment are strongly hoped for in Japan, and the system has also attracted much attention in overseas markets, with future developments expected.

Kedclean cleaning solutions for medical instruments

Kedclean, a medical abrasive solution for shower cleaning, reduces the burden and the cost of instrument cleaning.

For more details about the research seeds, please visit our website: http://www.crieto.hosp.tohoku.ac.jp/seedlist/
We participate in the development of the ‘Tokai Translational Research Center Development Network (TTC)’, in the Tohoku region, in the Academic Research Consortium (ARC), a national organization, the Clinical Research Protection Council, a national university hospital, Clinical Research Core Hospital Network, clinical research association, etc. The purpose of this initiative is to promote the development of core competencies related to research, innovation, and research and development in the Tohoku region.

Dr. Togoe’s research and specialized areas

- Development of new treatment methods and technologies
- Innovation in clinical practice
- Research on rare diseases
- Extracorporeal shock wave therapy
- Ultrasound wave angiogenesis therapy

4. Development of leading-edge circulatory organ treatment

We are also committed to serving as a translational bridge for the establishment of development strategies.

Dr. Takase’s research and specialized areas

- Development of leading-edge circulatory organ treatment
- Extracorporeal shock wave therapy
- Ultrasound wave angiogenesis therapy

We are also promoting the establishment of development strategies.

Dr. Takase’s research and specialized areas

- Development of leading-edge circulatory organ treatment
- Extracorporeal shock wave therapy
- Ultrasound wave angiogenesis therapy

We are also promoting the establishment of development strategies.

Dr. Takase’s research and specialized areas

- Development of leading-edge circulatory organ treatment
- Extracorporeal shock wave therapy
- Ultrasound wave angiogenesis therapy

The Rapid Clinical Research Unit is collaborating closely with the Nuclear Medicine, Nuclear Pharmacy Research Department, and Radiation Protection and Safety Control Division of the Cyclotron and Radiation Center (CRRC) of Akabane Campus, and the RCT groups inside the university hospital-Diagnostic Radiology, Radiological Science, Pharmaceutical Department, etc to rigorously conduct clinical trial using RCT specific imaging.

Dr. Inoue’s research and specialized areas

- Development of leading-edge circulatory organ treatment
- Extracorporeal shock wave therapy
- Ultrasound wave angiogenesis therapy

We are also promoting the establishment of development strategies.

Dr. Inoue’s research and specialized areas

- Development of leading-edge circulatory organ treatment
- Extracorporeal shock wave therapy
- Ultrasound wave angiogenesis therapy

We are also promoting the establishment of development strategies.

Dr. Inoue’s research and specialized areas

- Development of leading-edge circulatory organ treatment
- Extracorporeal shock wave therapy
- Ultrasound wave angiogenesis therapy

We are also promoting the establishment of development strategies.